ArticleMolecular cancer2020

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer.

Jung Min Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.